Fluxergy Announces Improved Clinical Performance of Its CE-IVD COVID-19 PCR Test

Fluxergy Announces Improved Clinical Performance of Its CE-IVD COVID-19 PCR Test

IRVINE, CA. - News Aktuell - 11 May 2021 - Fluxergy, Inc., a U.S. medical diagnostic point-of-care platform company with a detection technology solution capable of multiplexity and multimodality, is further announcing improved clinical performance of its CE-IVD COVID-19 RT-PCR test. The CE marking for its one-hour COVID-19 Test Kit allows healthcare professionals to use its in vitro diagnostics (IVD) assay for the detection of SARS-CoV-2. Fluxergy's innovative testing platform is approved for IVD use in the European Union market and any other markets that accept CE marking as valid regulatory approval. The Fluxergy
    Prev         Next    
Phiên bản di động